Drugs / Lasmiditan
Lasmiditan
also known as
COL-144 · LTN · Lasmiditan hemisuccinate · LASMIDITAN SUCCINATE · LY-573144 · LY-683974 · Rayvow · Reyvow
Small molecule targets HTR1F via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Rayvow | — | 2022-08-17 | europa.eu ↗ |
| Approved | US (FDA) | REYVOW | — | 2019-10-11 | fda.gov ↗ |
Trials 32 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 122 trials | ||||||
| Phase 1 | NCT04881747 | May → Jul 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04749914 | Feb → Jul 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04081324 | Nov 2019 → Jun 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03937648 | Aug → Oct 2019 | — | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT03988088 | Jul 2019 → Jan 2020 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03579940 | Jun → Aug 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03459612 | Mar → Jun 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03406260 | Jan → Apr 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03310411 | Oct → Dec 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03308669 | Oct → Dec 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03286218 | Sep → Nov 2017 | substance abuse | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03270644 | Aug → Nov 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03247790 | Aug 2017 → Jan 2018 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03252015 | Aug 2017 → Jan 2018 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03182920 | Jun → Aug 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03040362 | Apr → May 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03009162 | Apr → Jun 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03076970 | Mar → Apr 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03040479 | Mar → Jul 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03012334 | Jan → Jun 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02233296 | Jan → Feb 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03465436 | Sep → Dec 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03962738 | May 2019 → Jun 2020 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00883051 | Jul 2009 → Feb 2010 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00384774 | Nov 2006 → Jun 2007 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT04396574 | Jun 2020 → Dec 2025 | migraine disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT04396236 | Jun 2020 → Nov 2025 | migraine disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT04218162 | Mar → Oct 2020 | migraine disorder | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03670810 | Jun 2019 → Jun 2020 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02605174 | May 2016 → Jun 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02565186 | Oct 2015 → Aug 2019 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02439320 | Apr 2015 → Jul 2016 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lasmiditan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02565186 ↗30 |
| Known as | COL-144 | “Lasmiditan (COL-144) is a novel, centrally acting, highly selective” PMID 22459549 ↗ Mar 2012 |
| Known as | Lasmiditan hemisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Known as | LASMIDITAN SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Known as | LTN | “To evaluate the efficacy of lasmiditan (LTN) in treating migraine attacks of mild vs. moderate or severe pain intensity.” PMID 33784930 ↗ Apr 20211“Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults.” PMID 34742230 ↗ Nov 2021 |
| Known as | LY-573144 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Known as | LY-683974 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Known as | Rayvow | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Known as | Reyvow | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039520 ↗ |
| Action | Activate | “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL3039520 ↗1“potent agonist at 5-HT(1F) receptors” PMID 20855362 ↗ Jun 2010 |
| Modality | Small molecule | — CHEMBL3039520 ↗ |
| Route | Intravenous | “Administered as intravenous infusion” NCT00384774 ↗ |
| Target | HTR1F | “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL3039520 ↗ |